Literature DB >> 15048709

Systemic administration of antigen-loaded CD40-deficient dendritic cells mimics soluble antigen administration.

Kristin Hochweller1, Stephen M Anderton.   

Abstract

The decision to mount a T cell response to antigen (Ag) is dependent on the cellular context in which the Ag is presented. Activated dendritic cells (DC) are potent stimulators of immune responses, an ability which is linked to their high expression of several costimulatory molecules. In contrast, resting DC have been implicated in the generation of self tolerance, presumably due to their reduced costimulatory capacity. However, the precise molecular basis for the choice between Ag-induced immunity and unresponsiveness remains unclear. We show here that CD40 plays an important rolein this decision. Systemic administration of Ag-loaded, CD40-deficient DC failed to induce a productive primary T cell expansion and rendered mice relatively unresponsive to subsequent immunization with Ag in adjuvant. Using a TCR-transgenic T cell transfer system, we found that CD40(-/-) DC triggered an initial T cell activation that could not be sustained, resulting in loss of Ag-reactive T cells and reduced cytokine production by those T cells that did persist. Furthermore, administration of CD40(-/-) DC that had been loaded with a central nervous system autoantigen was found to protect mice from autoimmune pathology. These data implicate the CD40:CD40L interaction as a key checkpoint in the development of T cell immunity rather than tolerance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15048709     DOI: 10.1002/eji.200324782

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease.

Authors:  Husein Hadeiba; Tohru Sato; Aida Habtezion; Cecilia Oderup; Junliang Pan; Eugene C Butcher
Journal:  Nat Immunol       Date:  2008-10-05       Impact factor: 25.606

2.  Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype.

Authors:  Kathryn M Silk; Alison J Leishman; Kevin P Nishimoto; Anita Reddy; Paul J Fairchild
Journal:  J Biomed Biotechnol       Date:  2012-02-07

3.  Unconventional maturation of dendritic cells induced by particles from the laminated layer of larval Echinococcus granulosus.

Authors:  Cecilia Casaravilla; Alvaro Pittini; Dominik Rückerl; Paula I Seoane; Stephen J Jenkins; Andrew S MacDonald; Ana M Ferreira; Judith E Allen; Alvaro Díaz
Journal:  Infect Immun       Date:  2014-05-19       Impact factor: 3.441

Review 4.  Translational utility of experimental autoimmune encephalomyelitis: recent developments.

Authors:  Andre Ortlieb Guerreiro-Cacais; Hannes Laaksonen; Sevasti Flytzani; Marie N'diaye; Tomas Olsson; Maja Jagodic
Journal:  J Inflamm Res       Date:  2015-11-13

5.  CD40 signaling augments IL-10 expression and the tolerogenicity of IL-10-induced regulatory dendritic cells.

Authors:  Wojciech Dawicki; Hui Huang; Yanna Ma; Jennifer Town; Xiaobei Zhang; Chris D Rudulier; John R Gordon
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240

Review 6.  Cell replacement therapy and the evasion of destructive immunity.

Authors:  Paul J Fairchild; Nathan J Robertson; Siân Cartland; Kathleen F Nolan; Herman Waldmann
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

7.  TLR-4 ligation of dendritic cells is sufficient to drive pathogenic T cell function in experimental autoimmune encephalomyelitis.

Authors:  Richard J Mellanby; Helen Cambrook; Darryl G Turner; Richard A O'Connor; Melanie D Leech; Florian C Kurschus; Andrew S MacDonald; Bernd Arnold; Stephen M Anderton
Journal:  J Neuroinflammation       Date:  2012-10-30       Impact factor: 8.322

8.  CD4 memory T cells survive and proliferate but fail to differentiate in the absence of CD40.

Authors:  Megan MacLeod; Mark J Kwakkenbos; Alison Crawford; Sheila Brown; Brigitta Stockinger; Koen Schepers; Ton Schumacher; David Gray
Journal:  J Exp Med       Date:  2006-03-20       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.